Public health · 2026
Availability of medications for opioid use disorder and hepatitis C services in New York state jails: The New York state integrated jail survey.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Riback Lindsey R, Pourtaher Elham, Mason Shannon, Rowe Kirsten, Ellendon Narelle, Fallico Matthew, Flanigan Colleen, Akiyama Matthew J
Аннотация
OBJECTIVES: There is a significant knowledge gap regarding medication for opioid use disorder (MOUD) and hepatitis C virus (HCV) service provision in U.S. jails. To address this gap, characterized screening, treatment, and discharge planning capacity for OUD and HCV in New York State (NYS) jails outside of New York City.
STUDY DESIGN: Cross-sectional study.
METHODS: Between August and September 2022, 46 of 58 (80%) NYS jails completed a NYS Department of Health survey to determine jails' capacities to implement MOUD and capacity to screen, test and treat HCV. Surveys were completed prior to the October 2022 statewide mandate deadline to provide MOUD in jails.
RESULTS: Most (90%) NYS jails reported offering MOUD care continuation for individuals entering their facilities and 88% offered MOUD initiation. Naltrexone was most frequently used for initiation (67%) and buprenorphine for continuation (79%). Self-reported staff capacity to provide HCV screening was high (89%), yet 41% offered routine opt-in HCV screening and only 15% offered opt-out. Most facilities (84%) continued HCV treatment, though only 29% initiated treatment for newly diagnosed individuals. Although half of facilities (51%) had referral agreements with a community provider to facilitate post-release linkage, limited rapid test kits and education resources were barriers to jail-based HCV services.
CONCLUSIONS: MOUD availability in NYS jails is promising, but limited HCV service availability suggests support is needed to overcome financial and structural barriers. Strategies such as universal opt-out testing at intake, and task shifting jail-based discharge planning from staff to patient/peer navigators could significantly improve care in jail settings and during reentry.
STUDY DESIGN: Cross-sectional study.
METHODS: Between August and September 2022, 46 of 58 (80%) NYS jails completed a NYS Department of Health survey to determine jails' capacities to implement MOUD and capacity to screen, test and treat HCV. Surveys were completed prior to the October 2022 statewide mandate deadline to provide MOUD in jails.
RESULTS: Most (90%) NYS jails reported offering MOUD care continuation for individuals entering their facilities and 88% offered MOUD initiation. Naltrexone was most frequently used for initiation (67%) and buprenorphine for continuation (79%). Self-reported staff capacity to provide HCV screening was high (89%), yet 41% offered routine opt-in HCV screening and only 15% offered opt-out. Most facilities (84%) continued HCV treatment, though only 29% initiated treatment for newly diagnosed individuals. Although half of facilities (51%) had referral agreements with a community provider to facilitate post-release linkage, limited rapid test kits and education resources were barriers to jail-based HCV services.
CONCLUSIONS: MOUD availability in NYS jails is promising, but limited HCV service availability suggests support is needed to overcome financial and structural barriers. Strategies such as universal opt-out testing at intake, and task shifting jail-based discharge planning from staff to patient/peer navigators could significantly improve care in jail settings and during reentry.